Phathom Pharmaceuticals, Inc.

Hello and welcome to the Fathom Pharmaceuticals third quarter 2026 earnings results call. At this time, all participants are in a listen only mode. After the presentation, there will be a question and answer session. To ask a question during this time, you need to press star one one on your telephone keypad. Please be advised that today's call is being recorded. With that, I would like to turn the call over to Eric Sciorilli, Fathom's head of investor relations. Please go ahead.

Thank you, operator.

Hello, everyone, and thank you for joining us this morning to discuss Fathom's third quarter 2026 results. This morning's presentation will include remarks from Steve Basta, our president and CEO, and Sanjeev Narula, our chief financial and business officer. Before we begin, let me remind you that we'll be making a number of forward-looking statements throughout today's presentation. These forward-looking statements involve risks and uncertainties, many of which are beyond Fathom's control. Actual results may materially differ from the forward-looking statements, and any such risks We will be commenting on both gap and non-gap financial measures. specifically in the scope of this discussion when we refer to cash operating expenses, please note we are referring to the non-GAAP form of this measure, which excludes non-cash stock-based compensation. As always, detailed reconciliations between our non-GAAP results and the most directly comparable GAAP measures are included in this morning's press release. With that, I will now turn the call over to Steve Basta, Fathom's President and CEO, to kick us off. Steve?